{"id":192643,"date":"2025-11-21T14:07:16","date_gmt":"2025-11-21T14:07:16","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/192643\/"},"modified":"2025-11-21T14:07:16","modified_gmt":"2025-11-21T14:07:16","slug":"clinical-perspectives-of-new-insights-and-tools-to-minimize-the-hypoglycaemia-burden-connected-with-type-2-diabetes-pharmacotherapy-cardiovascular-diabetology","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/192643\/","title":{"rendered":"Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy | Cardiovascular Diabetology"},"content":{"rendered":"
  • \n

    Amiel SA. The consequences of hypoglycaemia. Diabetologia. 2021;64(5):963\u201370. https:\/\/doi.org\/10.1007\/s00125-020-05366-3<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    American Diabetes Association. 6. Glycemic goals and hypoglycaemia: standards of care in diabetes\u20142025. Diabetes Care. 2025;48(Supple. 1):S128\u201345. https:\/\/doi.org\/10.2337\/dc25-S006<\/a>.<\/p>\n<\/li>\n

  • \n

    International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7:385\u201396.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Mellor J, Kuznetsov D, Heller S, Gall MA, Rosilio M, Amiel SA, et al. Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials. Diabetologia. 2024;67(10):2210\u201324. https:\/\/doi.org\/10.1007\/s00125-024-06225-1<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Bhatt DL, Bloomgarden ZT, et al. DCRM 2.0: multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024;159:155931. https:\/\/doi.org\/10.1016\/j.metabol.2024.155931<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int J Mol Sci. 2014;15(10):18381\u2013406. https:\/\/doi.org\/10.3390\/ijms151018381<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol. 2019;26(Suppl. S2):7\u201314. https:\/\/doi.org\/10.1177\/2047487319881021<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    IDF Diabetes Atlas International Diabetes Federation; 2025 [cited 2025 6\/05\/2025]. Available from: https:\/\/diabetesatlas.org\/.diabres.2023.110945<\/a>.<\/p>\n<\/li>\n

  • \n

    Zhou B. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077\u201393.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383(9933):2008\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(14)60794-7<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Schnell O, Barnard-Kelly K, Battelino T, et al. CVOT summit report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. 2024;23:104. https:\/\/doi.org\/10.1186\/s12933-024-02180-8<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rick TJ. FDA\u2019s new guidance for industry addressing evaluation of the safety of new drugs for improving glycemic control: a case study in regulatory science. Ther Innov Regul Sci. 2021;55(1):1\u20135.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    FDA. Guidance for industry diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes \u2013 guidance Document2008. Available from: https:\/\/www.regulations.gov\/document\/FDA-2008-D-0118-0029<\/a>.<\/p>\n<\/li>\n

  • \n

    Standl E, Schnell O. Treatment paradigm shifting implications of recent cardiovascular outcome trials: core insights on the brink of the 2020ies. Diabetes Res Clin Pract. 2020;161:108054.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Heller SR, Geybels MS, Iqbal A, Liu L, Wagner L, Chow E. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia. 2022;65(1):55\u201364. https:\/\/doi.org\/10.1007\/s00125-021-05556-7<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Mellbin LG, Malmberg K, Waldenstr\u00f6m A, Wedel H, Ryd\u00e9n L, DIGAMI 2 Investigators. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type2 diabetes: a report from the DIGAMI 2 trial. Heart. 2009;95:721\u20137.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Mellbin LG, Ryd\u00e9n L, Riddle MC, ORIGIN Trial Investigators, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013;34:3137\u201344.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, et al. Devote 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018;61(1):58\u201365. https:\/\/doi.org\/10.1007\/s00125-017-4422-0<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Standl E, Stevens SR, Armstrong PW, TECOS Study Group, et al. Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype. Diabetes Care. 2018;41:596\u2013603. https:\/\/doi.org\/10.2337\/dc17-1778<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wightman H, Butterly E, Wei L, McChrystal R, Sattar N, Adler A, et al. Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: an individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events. PLoS Med. 2025;22(4):e1004553. https:\/\/doi.org\/10.1371\/journal.pmed.1004553<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Standl E, Stevens SR, Lokhnygina Y, EXSCEL Study Group, et al. Confirming the bidirectional nature of the association between severe hypoglycemic and cardiovascular events in type 2 diabetes: insights from EXSCEL. Diabetes Care. 2020;43(3):643\u201352. https:\/\/doi.org\/10.2337\/dc19-1079<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155\u201366. https:\/\/doi.org\/10.1001\/jama.2019.13772<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rosenstock J, Perkovic V, Johansen OE, CARMELINA Investigators, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69\u201379. https:\/\/doi.org\/10.1001\/jama.2018.18269<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Ryd\u00e9n L, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068. https:\/\/doi.org\/10.1136\/bmj-2022-074068<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    The GRADE Study Research Group. Glycaemia reduction in type 2 diabetes\u2014glycemic outcomes. N Engl J Med. 2022;387:1063\u201374.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    The GRADE Study Research Group. Glycaemia reduction in type 2 diabetes\u2014microvascular and cardiovascular outcomes. N Engl J Med. 2022;387:1075\u201388.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ryd\u00e9n L, Standl E. After metformin\u2014next steps for type 2 diabetes with low cardiovascular risk. N Engl J Med. 2022;387(12):1136\u20138. https:\/\/doi.org\/10.1056\/NEJMe2210531<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes [published correction appears in N Engl J Med 2009; 361:1028; N Engl J Med 2009; 361:1024\u20135]. N Engl J Med 2009; 360:129\u201339.<\/p>\n<\/li>\n

  • \n

    Zoungas S, Patel A, Chalmers J, ADVANCE Collaborative Group, et al. Severe hypoglycaemia and risks of vascular events and death. N Engl J Med. 2010;363:1410\u20138.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Marx N, Kolkailah AA, Rosenstock J, Johansen OE, Cooper ME, Alexander JH, et al. Hypoglycaemia and cardiovascular outcomes in the CARMELINA and CAROLINA trials of linagliptin: a secondary analysis of randomized clinical trials. JAMA Cardiol. 2024;9(2):134\u201343. https:\/\/doi.org\/10.1001\/jamacardio.2023.4602<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043\u2013140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533. https:\/\/doi.org\/10.1136\/bmj.f4533<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zaccardi F, Ling S, Lawson C, Davies MJ, Khunti K. Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study. Diabetologia. 2020;63:2129\u201339.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Standl E, Schnell O. Increased risk of cancer-an integral component of the cardio-renal-metabolic disease cluster and its management. Cells. 2025;14(8):564. https:\/\/doi.org\/10.3390\/cells14080564<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Heller S, Lingvay I, Marso SP, Philis-Tsimikas A, Pieber TR, Poulter NR, et al. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. Diabetes Obes Metab. 2020;22(12):2241\u20137. https:\/\/doi.org\/10.1111\/dom.14049<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Song SH, Frier BM. Severe hypoglycaemia and diabetic ketoacidosis in adults presenting to a hospital emergency department: adverse prognostic markers for survival in type 2 diabetes and the role of SGLT2 inhibitors. Diabet Med. 2025;42(3):e15466. https:\/\/doi.org\/10.1111\/dme.15466<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med. 2011;124(11):993\u20136. https:\/\/doi.org\/10.1016\/j.amjmed.2011.08.008<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tsujimoto T, Yamamoto-Honda R, Kajio H, et al. Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycaemia in type 1 and type 2 diabetic patients. Diabetes Care. 2014;37(1):217\u201325. https:\/\/doi.org\/10.2337\/dc13-0701<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycaemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26:1485\u20139.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycaemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2009;58:360\u20136.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Stahn A, Pistrosch F, Ganz X, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycaemias and silent arrhythmias. Diabetes Care. 2014;37:516\u201320.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Iqbal A, Prince LR, Novodvorsky P, Bernjak A, Thomas MR, Birch L, et al. Effect of hypoglycemia on inflammatory responses and the response to low-dose endotoxemia in humans. J Clin Endocrinol Metab. 2019;104(4):1187\u201399. https:\/\/doi.org\/10.1210\/jc.2018-01168<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Chow E, Iqbal A, Walkinshaw E, Phoenix F, Macdonald IA, Storey RF, et al. Prolonged prothrombotic effects of antecedent hypoglycaemia in individuals with type 2 diabetes. Diabetes Care. 2018;41(12):2625\u201333. https:\/\/doi.org\/10.2337\/dc18-0050<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Verhulst CEM, van Heck JIP, Fabricius TW, Stienstra R, Teerenstra S, McCrimmon RJ, et al. Hypoglycaemia induces a sustained pro-inflammatory response in people with type 1 diabetes and healthy controls. Diabetes Obes Metab. 2023;25(11):3114\u201324. https:\/\/doi.org\/10.1111\/dom.15205<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Verhulst CEM, van Heck JIP, Fabricius TW, Stienstra R, Teerenstra S, McCrimmon RJ, et al. Sustained proinflammatory effects of hypoglycaemia in people with type 2 diabetes and in people without diabetes. Diabetes. 2022;71(12):2716\u201327. https:\/\/doi.org\/10.2337\/db22-0246<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Li G, Zhong S, Wang X, Zhuge F. Association of hypoglycaemia with the risks of arrhythmia and mortality in individuals with diabetes – a systematic review and meta-analysis. Front Endocrinol. 2023;14:1222409. https:\/\/doi.org\/10.3389\/fendo.2023.1222409<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jordan J, Birkenfeld AL, Melander O, Moro C. Natriuretic peptides in cardiovascular and metabolic crosstalk: implications for hypertension management. Hypertension. 2018;72:270\u20136.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cou\u00e9 M, Barquissau V, Morigny P, et al. Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes. Sci Rep. 2018;8:1097.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jungmann E, Konzok C, H\u00a8oll E, Fassbinder W, Sch\u00f6ffling K. Effect of human atrial natriuretic peptide on blood glucose concentrations and hormone stimulation during insulin-induced hypoglycaemia in healthy man. Eur J Clin Pharmacol. 1989;36:593\u20137.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Standl E, Schnell O, McGuire DK. Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res. 2016;118:1830\u201343.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Regan JA, Mentz RJ, Nguyen M, Green JB, Truby LK, Ilkayeva O, et al. Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight. 2023;8:e168563. https:\/\/doi.org\/10.1172\/jci.insight.168563<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 to 24 years (UKPDS 91). Lancet. 2024;404:145\u201355.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    American Diabetes Association. Summary of revisions: standards of care in Diabetes\u20142025. Diabetes Care. 2025;48(Suppl. 1):S6\u201313. https:\/\/doi.org\/10.2337\/dc25-SREV<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Reaven PD, Newell M, Rivas S, Zhou X, Norman GJ, Zhou JJ. Initiation of continuous glucose monitoring is linked to improved glycemic control and fewer clinical events in type 1 and type 2 diabetes in the Veterans Health Administration. Diabetes Care. 2023;46(4):854\u201363. https:\/\/doi.org\/10.2337\/dc22-2189<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Nathanson D, Eeg-Olofsson K, Spelman T, et al. Intermittently scanned continuous glucose monitoring compared with blood glucose monitoring is associated with lower HbA1c and a reduced risk of hospitalisation for diabetes-related complications in adults with type 2 diabetes on insulin therapies. Diabetologia. 2025;68:41\u201351. https:\/\/doi.org\/10.1007\/s00125-024-06289-z<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ajjan RA, Battelino T, Cos X, Del Prato S, Philips JC, Meyer L, et al. Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nat Rev Endocrinol. 2024;20(7):426\u201340.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Battelino T, Lalic N, Hussain S, Ceriello A, Klobucar S, Davies SJ, et al. The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycaemia or type 2 diabetes. Diabetes Res Clin Pract. 2025;223:112111. https:\/\/doi.org\/10.1016\/j.diabres.2025.112111<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zhou X, Zeng C. Diabetes remission of bariatric surgery and nonsurgical treatments in type 2 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23:46. https:\/\/doi.org\/10.1186\/s12902-023-01283-9<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Borges-Canha M, Neves JS, Silva MM, et al. Prediabetes remission after bariatric surgery: a 4-years follow-up study. BMC Endocr Disord. 2024;24:7. https:\/\/doi.org\/10.1186\/s12902-024-01537-0<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kahn SE, Deanfield JE, Jeppesen OK, Emerson SS, Boesgaard TW, Colhoun HM, et al. Effect of Semaglutide on regression and progression of glycaemia in people with overweight or obesity but without diabetes in the SELECT trial. Diabetes Care. 2024;47(8):1350\u20139. https:\/\/doi.org\/10.2337\/dc24-0491<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2410819<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Kelly T, Irvine K, Peters C, Zhyzhneuskaya S. et al. 2024 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12:233\u201346. Erratum in Lancet Diabetes Endocrinol. 12:e17.<\/p>\n<\/li>\n","protected":false},"excerpt":{"rendered":"Amiel SA. The consequences of hypoglycaemia. Diabetologia. 2021;64(5):963\u201370. https:\/\/doi.org\/10.1007\/s00125-020-05366-3. Article\u00a0 CAS\u00a0 PubMed\u00a0 PubMed Central\u00a0 Google Scholar\u00a0 American Diabetes…\n","protected":false},"author":2,"featured_media":192644,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[7233,107285,2908,6920,9835,2675,18,135,107284,19,17,107286,107283],"class_list":{"0":"post-192643","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-angiology","9":"tag-bi-directional-association","10":"tag-cardiology","11":"tag-cardiovascular-events","12":"tag-continuous-glucose-monitoring","13":"tag-diabetes","14":"tag-eire","15":"tag-health","16":"tag-hypoglycaemia","17":"tag-ie","18":"tag-ireland","19":"tag-phenotype-at-dual-risk","20":"tag-type-2-diabetes-pharmacotherapy"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115588080818461501","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/192643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=192643"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/192643\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/192644"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=192643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=192643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=192643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}